Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Visani

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Leukemia & Lymphoma|February 23, 2011
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomideMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Haematologica|December 7, 2007
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II StudyPier Paolo Piccaluga, Michele Malagola, Michela Rondoni, et al.
British Journal of Haematology|November 28, 2008
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised studyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
American Journal of Hematology|March 11, 2015
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-upFederico Mosna, Cristina Papayannidis, Giovanni Martinelli, et al.
Haematologica|July 18, 2012
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitorsAntonella Russo Rossi, Massimo Breccia, Elisabetta Abruzzese, et al.
Hematological Oncology|July 21, 2012
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemiaRoberto Latagliata, Massimo Breccia, Carmen Fava, et al.
Haematologica|January 26, 2006
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II studyMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Blood|August 30, 2002
Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experienceAlessandro Pulsoni, Livio Pagano, Francesco Lo Coco, et al.
Haematologica|March 17, 2004
Survival of elderly patients with acute myeloid leukemiaAlessandro Pulsoni, Livio Pagano, Roberto Latagliata, et al.
Blood|August 6, 2011
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patientsGiuseppe Visani, Lara Malerba, Pietro Maria Stefani, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Leukemia & Lymphoma|February 23, 2011
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomideMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Haematologica|December 7, 2007
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II StudyPier Paolo Piccaluga, Michele Malagola, Michela Rondoni, et al.
British Journal of Haematology|November 28, 2008
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised studyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
American Journal of Hematology|March 11, 2015
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-upFederico Mosna, Cristina Papayannidis, Giovanni Martinelli, et al.
Haematologica|July 18, 2012
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitorsAntonella Russo Rossi, Massimo Breccia, Elisabetta Abruzzese, et al.
Hematological Oncology|July 21, 2012
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemiaRoberto Latagliata, Massimo Breccia, Carmen Fava, et al.
Haematologica|January 26, 2006
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II studyMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Blood|August 30, 2002
Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experienceAlessandro Pulsoni, Livio Pagano, Francesco Lo Coco, et al.
Haematologica|March 17, 2004
Survival of elderly patients with acute myeloid leukemiaAlessandro Pulsoni, Livio Pagano, Roberto Latagliata, et al.
Blood|August 6, 2011
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patientsGiuseppe Visani, Lara Malerba, Pietro Maria Stefani, et al.
Pageof 11